SILENCE THERAPEUTICS PLC-ADR (SLN) Stock Price, Forecast & Analysis

NASDAQ:SLN • US82686Q1013

4.54 USD
+0.21 (+4.85%)
Last: Feb 12, 2026, 08:16 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News

SLN Key Statistics, Chart & Performance

Key Statistics
Market Cap214.44M
Revenue(TTM)N/A
Net Income(TTM)N/A
Shares47.23M
Float129.28M
52 Week High7.78
52 Week Low1.97
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)N/A
PEN/A
Fwd PEN/A
Earnings (Next)02-27
IPO2010-01-05
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
SLN short term performance overview.The bars show the price performance of SLN in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20 -30

SLN long term performance overview.The bars show the price performance of SLN in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of SLN is 4.54 USD. In the past month the price decreased by -22.66%. In the past year, price decreased by -6.2%.

SILENCE THERAPEUTICS PLC-ADR / SLN Daily stock chart

SLN Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating
SLN Full Technical Analysis Report

SLN Financial Highlights


Industry RankSector Rank
PM (TTM) N/A
ROA N/A
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%N/A
Sales Q2Q%N/A
EPS 1Y (TTM)N/A
Revenue 1Y (TTM)N/A
SLN financials

SLN Forecast & Estimates


Analysts
Analysts84
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A
SLN Analyst EstimatesSLN Analyst Ratings

SLN Ownership

Ownership
Inst Owners16.5%
Ins Owners8.76%
Short Float %1.03%
Short Ratio4.24
SLN Ownership

SLN Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABBV ABBVIE INC15.67402.079B
AMGN AMGEN INC16.25197.191B
GILD GILEAD SCIENCES INC17.02188.348B
VRTX VERTEX PHARMACEUTICALS INC22.81117.985B
REGN REGENERON PHARMACEUTICALS16.8782.362B
ALNY ALNYLAM PHARMACEUTICALS INC46.0540.753B
INSM INSMED INC N/A31.174B
BIIB BIOGEN INC12.8528.692B
NTRA NATERA INC N/A28.683B
UTHR UNITED THERAPEUTICS CORP16.1620.502B

Related stock screener links

View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges

About SLN

Company Profile

SLN logo image Silence Therapeutics PLC is a GB-based company operating in Biotechnology industry. Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The firm leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The firm focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca.

Company Info

SILENCE THERAPEUTICS PLC-ADR

72 Hammersmith Road

London W14 8TH GB

CEO: Mark Rothera

Employees: 116

SLN Company Website

Phone: 442034576900

SILENCE THERAPEUTICS PLC-ADR / SLN FAQ

What does SLN do?

Silence Therapeutics PLC is a GB-based company operating in Biotechnology industry. Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The firm leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The firm focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca.


What is the stock price of SILENCE THERAPEUTICS PLC-ADR today?

The current stock price of SLN is 4.54 USD. The price increased by 4.85% in the last trading session.


Does SILENCE THERAPEUTICS PLC-ADR pay dividends?

SLN does not pay a dividend.


What is the ChartMill rating of SILENCE THERAPEUTICS PLC-ADR stock?

SLN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.


Can you provide the upcoming earnings date for SILENCE THERAPEUTICS PLC-ADR?

SILENCE THERAPEUTICS PLC-ADR (SLN) will report earnings on 2026-02-27, before the market open.


Who owns SILENCE THERAPEUTICS PLC-ADR?

You can find the ownership structure of SILENCE THERAPEUTICS PLC-ADR (SLN) on the Ownership tab.